Analysis of tumor growth rate for radioiodine (RAI)-refractory differentiated thyroid cancer patients receiving placebo and/or sorafenib in the phase III DECISION study

被引：0
|
作者：
Fassnacht, M. [1 ]
Kappeler, C. [2 ]
Healy, D. P. [3 ]
Baumer, C. [4 ]
Meinhardt, G. [3 ]
Elisei, R. [5 ]
Schlumberger, M. [6 ,7 ]
Brose, M. S. [8 ]
机构：
[1] Univ Klinikum Wurzburg, Wurzburg, Germany
[2] Bayer Pharma AG, Berlin, Germany
[3] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[4] BIOP AG, Basel, Switzerland
[5] Univ Pisa, Pisa, Italy
[6] Gustave Roussy, Villejuif, France
[7] Univ Paris 11, Villejuif, France
[8] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0277
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [21] Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer
    Marcia S Brose
    Christopher M Nutting
    Steven I Sherman
    Young Kee Shong
    Johannes WA Smit
    Gerhard Reike
    John Chung
    Joachim Kalmus
    Christian Kappeler
    Martin Schlumberger
    BMC Cancer, 11
  • [22] Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer
    Brose, Marcia S.
    Nutting, Christopher M.
    Sherman, Steven I.
    Shong, Young Kee
    Smit, Johannes W. A.
    Reike, Gerhard
    Chung, John
    Kalmus, Joachim
    Kappeler, Christian
    Schlumberger, Martin
    BMC CANCER, 2011, 11
  • [23] Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.
    Bastholt, Lars
    Brose, Marcia S.
    Jarzab, Barbara
    Schlumberger, Martin
    Siena, Salvatore
    De La Fouchardiere, Christelle
    Paschke, Ralf
    Deshpande, Hari Anant
    Shi, Yuankai
    Elisei, Rossella
    Gao, Ming
    Li, Lin
    Prins, Klaas
    Walker, Helen
    Mitchell, David Y.
    Lettieri, John T.
    Molnar, Istvan
    Kappeler, Christian
    Pena, Carol Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma
    Sherman, Eric Jeffrey
    Ho, Alan Loh
    Fury, Matthew G.
    Baxi, Shrujal S.
    Haque, Sofia
    Korte, Susan H.
    Smith-Marrone, Stephanie
    Xiao, Han
    Ghossein, Ronald A.
    Fagin, James A.
    Pfister, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial
    Paschke, R.
    Brose, M. S.
    Jarzab, B.
    Elisei, R.
    Siena, S.
    Bastholt, L.
    de la Fouchardiere, C.
    Pacini, F.
    Nutting, C.
    Shong, Y. K.
    Sherman, S., I
    Smit, J. W. A.
    Chung, J.
    Kappeler, C.
    Molnar, I
    Schlumberger, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 120 - 120
  • [26] A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).
    Chen, Jiaying
    Ji, Qinghai
    Cao, Junning
    Ji, Dongmei
    Bai, Chunmei
    Lin, Yansong
    Pan, Bin
    Sun, Guofang
    Li, Jing
    Qi, Chuan
    Hua, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] Safety and tolerability of sorafenib for treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC): detailed analyses from the phase III DECISION trial
    Kroiss, M.
    Worden, F.
    Shi, J.
    Hadjieva, T.
    Bonichon, F.
    Gao, M.
    Fugazzola, L.
    Ando, Y.
    Hasegawa, Y.
    Park, D. J.
    Nutting, C.
    Sherman, S., I
    Shong, Y. K.
    Smit, J. W.
    Chung, J.
    Kapeller, C.
    Molnar, I
    Schlumberger, M.
    Brose, M. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 269 - 269
  • [28] Clinicopathological Features Predict Outcomes in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Real-World Study
    Cheng, Lin
    Fu, Hao
    Jin, Yuchen
    Sa, Ri
    Chen, Libo
    ONCOLOGIST, 2020, 25 (04): : e668 - e678
  • [29] RNAseq analysis of the sorafenib phase III DECISION trial in differentiated thyroid cancer (DTC): Correlation with clinical outcome.
    Capdevila, Jaume
    Garcia, Ignacio Matos
    Mancuso, Francesco M.
    Iglesias, Carmela
    Nuciforo, Paolo
    Zafon, Caries
    Palmer, Hector G.
    Ogbah, Zighereda
    Muinos, Laura
    Pena, Carol Elaine
    Brose, Marcia S.
    Schlumberger, Martin
    Vivancos, Ana
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial.
    Brose, Marcia S.
    Jarzab, Barbara
    Elisei, Rossella
    Siena, Salvatore
    Bastholt, Lars
    De La Fouchardiere, Christelie
    Pacini, Furio
    Paschke, Ralf
    Nutting, Christopher
    Shong, Young Kee
    Sherman, Steven I.
    Smit, Johannes W. A.
    Chung, John Woojune
    Kappeler, Christian
    Molnar, Istvan
    Schlumberger, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345